|Awarded On||August 20, 2014|
|Title||Accurate and High Throughput Detection of Breast and Ovarian Cancer Cells in Whole Blood|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The Methodist Hospital Research Institute|
|Principal Investigator/Program Director||Youli Zu|
|Cancer Sites||Breast, Ovary|
Accurate and High-Throughput Detection of Breast and Ovarian Cancer Cells in Whole Blood Metastasis, or spread of primary tumor cells, is the major cause of mortality in cancer patients. Studies have demonstrated that circulating tumor cells (CTCs) in the bloodstream are key players in establishing metastatic tumors. In addition, the presence of CTCs is directly associated with cancer progression, recurrence, and a poorer survival rate. Therefore, accurate and rapid CTC detection and quantification is needed for proper and timely cancer patient treatment. There is only one test system currently approved by the FDA for detecting cancer cells in the bloodstream, and it involves a lengthy isola...